The relation of glucose metabolism to left ventricular mass and function and sympathetic nervous system activity in obese subjects with metabolic syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Straznicky, Nora E ^a   Grima, Mariee T ^a   Sari, Carolina I ^a   Karapanagiotidis, Sofie ^a   Wong, Chiew ^a,b   Eikelis, Nina ^a   Richards, Katrina L ^a   Lee, Geraldine ^a   Nestel, Paul J ^a   Dixon, John B ^a,b   Lambert, Gavin W ^a,b   Schlaich, Markus P ^a,b   Lambert, Elisabeth A ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOMEGALY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE METABOLISM; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; OBESITY; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PULSE PRESSURE;

BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HEART VENTRICLES; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUSCLE, SKELETAL; NOREPINEPHRINE; OBESITY; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 84873645706     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3277     Document Type: Article

References (41)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87: 4-14.
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-2140.
3. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007; 116:151-157.
4. Ariza MA, Vimalananda VG, Rosenzweig JL. The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocrinol Metab Disord. 2010;11:1-10.
5. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcomes. Diabetologia. 2000;43:632-641.
6. Bonow RO, Gheorghiade M. The diabetes epidemic:Anational and global crisis. Am J Med. 2004;116:2S-10S.
7. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy. The search for a unifying hypothesis. Circ Res. 2006;98:596-605.
8. Perciaccante A, Fiorentini A, Paris A, Serra P, Tubani L. Circadian rhythm of the autonomic nervous system in insulin resistant subjects with normoglycemia, impaired fasting glycemia, impaired glucose tolerance, type 2 diabetes mellitus. BMC Cardiovascular Disorders. 2006;6:19.
9. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097-3101.
10. Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia. 2010;53:1331-1340.
11. Sciacqua A, Miceli S, Greco L, et al. One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care. 2011;34:2291-2296.
12. Dinh W, Lankisch M, Nickl W, et al. Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. Cardiovasc Diabetol. 2010;9:63.
13. Schindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77: 1017-1020.
14. Holmang A, Yoshida N, Jennische E, Waldenstrom A, Bjorntorp P. The effects of hyperinsulinemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest. 1996;26:973-978.
15. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
16. Florian JP, Pawelczyk JA. Non-esterified fatty acids increase arterial pressure via central sympathetic activity in humans. Clin Sci. 2010; 118:61-69.
17. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in human forearm. Hypertension. 1993;21:618-623.
18. Straznicky NE, Grima MT, Sari CI, et al. Neuroadrenergic dysfunction along the diabetic continuum: A comparative study in obese metabolic syndrome subjects. Diabetes. 2012;61:2506-2516.
19. Anan F, Masaki T, Yonemochi H, et al. Abdominal visceral fat accumulation is associated with the results of 123I-metaiodobenzyl-guanidine myocardial scintigraphy in type 2 diabetes. Eur J Nucl Med Mol Imaging. 2007;34:1189-1197.
20. Kiyono Y, Lida Y, Kawashima H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging. 2002; 29:999-1005.
21. Thackeray JT, Radziuk J, Harper ME, et al. Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance and hyperglycemia. Cardiovasc Diabetol. 2011;10:75.
22. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes. Association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol. 2004;44: 2368-2374.
23. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108: 560-565.
24. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640 -1645.
25. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IFD Consultation. Geneva, Switzerland: World Health Organization; 2006.
26. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18: 1440-1463.
27. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
28. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618.
29. Eisenhofer G. Sympathetic nerve function. Assessment by radioisotope dilution analysis. Clin Auton Res. 2005;15:264-283.
30. Eisenhofer G, Goldstein DS, Kopin IJ. Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clin Sci. 1989;76:171-182.
31. Straznicky NE, Lambert GW, Masuo K, et al. Blunted sympathetic neural response to oral glucose in obese subjects with the insulinresistant metabolic syndrome. Am J Clin Nutr. 2009;89:27-36.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
33. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;6:E214-E223.
34. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Man. 2010; 6:883-903.
35. Muniyappa R, Quon MJ. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care. 2007;10: 523-530.
36. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study, 1987-1998. Circulation. 2003;107: 2190-2195.
37. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006;29:914-919.
38. Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993;602:161-164.
39. Robertson SD, Matthies HJ, Owens WA, et al. Insulin reveals Akt signalling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J Neurosci. 2010;30: 11305-11316.
40. Kiyono Y, Kajiyama S, Fujiwara H, Kanegawa N, Saji H. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG. Eur J Nucl Med Mol Imaging. 2005;32: 438-442.
41. Rumantir MS, Kaye DM, Jennings GL, Vaz M, Hastings JA, Esler MD. Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension. 2000;36:824-829.